Adjuvant Anti–PD-1 Antibody Treatment in Stage III/IV Melanoma Is Cost-Effective
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Adjuvant Anti-PD-1 Antibody Treatment in Stage III/IV Melanoma: Real-World Experience and Health Economic Considerations
J Dtsch Dermatol Ges 2021 Jul 13;[EPub Ahead of Print], P Koelblinger, M Hoellwerth, MT Dernoscheg, L Koch, E Richtig, M Wanner, VA Nguyen, H Ostermann, JW Bauer, M LaimerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.